Internal Med

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Bhoopalam N et al. – Zoledronic acid improved bone mineral density in patients with M0 prostate cancer on androgen deprivation therapy for 1 year or less, or greater than 1 year. This finding indicates that bisphosphonate therapy remains effective when initiated later in the course of androgen deprivation therapy and is efficacious in Veterans Affairs patients with multiple risk factors for osteoporosis.

Related Articles

Osteologix to Continue Development of Osteoporosis Drug
Internet Source, 10/21/09    Relevance Score: 93%

Lifestyle increases osteoporosis risk: docs
Internet Source, 10/21/09    Relevance Score: 90%

Reducing hip fracture risk with risedronate in elderly women with established osteoporosis
Clinical Interventions in Aging, 11/12/09    Relevance Score: 89%

A microarray based identification of osteoporosis-related genes in primary culture of human osteoblasts
Bone, 10/27/09    Relevance Score: 89%

Evaluation of Compliance with Osteoporosis Treatment Guidelines After Initiation of a Pharmacist-Run Osteoporosis Service at a Family Medicine Clinic
Annals of Pharmacotherapy, 10/15/09    Relevance Score: 89%


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Sponsor

Send this Summary to a Colleague

Enter email address